| http://www.w3.org/ns/prov#value | - In its internal program Starpharma has announced significant tumour-targeting results in its docetaxel (Taxotere??) program, with animal studies showing its dendrimer-enhanced version of docetaxel to have significantly superior anti-cancer effects across a range of important cancer types including breast, prostate, lung and ovarian tumour, when compared to Taxotere?? (docetaxel).
|
